- Study protocol
- Open Access
European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG registry): Study Protocol for a Prospective Clinical Registry and Proposal of Classification of Postoperative Complications
Journal of Cardiothoracic Surgery volume 10, Article number: 90 (2015)
Clinical evidence in coronary surgery is usually derived from retrospective, single institutional series. This may introduce significant biases in the analysis of critical issues in the treatment of these patients. In order to avoid such methodological limitations, we planned a European multicenter, prospective study on coronary artery bypass grafting, the E-CABG registry.
The E-CABG registry is a multicenter study and its data are prospectively collected from 13 centers of cardiac surgery in university and community hospitals located in six European countries (England, Italy, Finland, France, Germany, Sweden). Data on major and minor immediate postoperative adverse events will be collected. Data on late all-cause mortality, stroke, myocardial infarction and repeat revascularization will be collected during a 10-year follow-up period. These investigators provided a score from 0 to 10 for any major postoperative adverse events and their rounded medians were used to stratify the severity of these complications in four grades. The sum of these scores for each complication/intervention occurring after coronary artery bypass grafting will be used as an additive score for further stratification of the prognostic importance of these events.
The E-CABG registry is expected to provide valuable data for identification of risk factors and treatment strategies associated with suboptimal outcome. These information may improve the safety and durability of coronary artery bypass grafting. The proposed classification of postoperative complications may become a valuable research tool to stratify the impact of such complications on the outcome of these patients and evaluate the burden of resources needed for their treatment.
Clinical Trials number
Myocardial revascularization is the most common cardiac surgical procedure. Although the efficacy and long-term durability of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) has been largely proved in a number of subsets of patients [1, 2], PCI along with its related technological advances has slowly become the most common invasive treatment method for coronary artery disease. The minimally invasive nature and the low risk of immediate adverse events are strong arguments in favor of PCI. However, the current durability of PCI is most likely inferior to that of CABG, particularly in patients with multivessel disease [1, 2], diabetes [2, 3] and renal failure .
Contrary to PCI, advancements in coronary surgery during the last decade have been slow and limited to improvements in perfusion and anesthesiological methods. Furthermore, clinical evidence in CABG is usually derived from retrospective and single institutional series and this may introduce significant biases in the analysis of critical issues in the treatment of these patients. However, since CABG is a major surgical procedure associated with postoperative mortality and significant morbidity, there is a need of improvements in the treatment of patients undergoing coronary surgery in order to reduce the risk of early and late adverse events. Prospective analyses of the impact of baseline risk factors, operative techniques, perioperative treatment methods and secondary prevention strategies on the outcome of patients undergoing surgical revascularization of the myocardium are expected to provide valuable and reliable information to improve the safety and durability of CABG.
Rationale of the study
Improvements in the surgical treatment of cardiac diseases are possible only when implementation of current methods and development of new methods are based on the solid ground of large and reliable clinical data . Knowledge on these issues can be generated by clinical prospective registries. The rationale of this European multicenter study on patients undergoing isolated CABG (E-CABG) is therefore to collect in a prospective fashion current data on baseline characteristics, operative and anesthesiological methods and postoperative outcome of patients undergoing CABG in several European centers of cardiac surgery.
Prospective clinical registries have a relevant role in clinical research as they differ from randomized clinical trials in many aspects. They require less resources and are not narrowly focused on specific subsets of patients, but rather provide data on general patient populations with limited exclusion criteria. Importantly, clinical registries may provide data on long-term outcome that exceed the study window of a trial . Clinical findings of registries assume even more significance when including study populations from different geographic areas with heterogeneous referral pathways, baseline clinical characteristics and perioperative treatment strategies.
The E-CABG has been planned to provide data with well-defined definition criteria and this paper is a summary of baseline, operative and postoperative variables. In particular, these investigators propose a grading system to stratify the severity of postoperative complications in patients undergoing adult cardiac surgery. This study is registered in Clinicaltrials.gov with the number NCT02319083.
Setting, design, study population, patient recruitment and study period
The E-CABG is an observational registry study and its data are prospectively collected consecutively from 13 centers of cardiac surgery of either university or community hospitals located in six European countries (England, Finland, France, Germany and Italy) (Table 1). Patients aged > 18 years undergoing isolated primary or redo CABG for stable coronary artery disease or acute coronary syndrome are eligible for inclusion in this prospective registry. Patients undergoing any other major cardiac surgery procedure will be excluded from this registry. However, patients who undergo CABG associated with Maze will be included in this registry. Patients are recruited in a consecutive series from each institution and their data collected in a specifically created Access-datasheet. The minimum recruitment period is 12 months (January 1 - December 31, 2015). Patients will be followed up after surgery for the following 10 years.
Data management and monitoring
Data will be collected in to a dedicated Access datasheet with predefined variables. Data including patients’ codes are stored in institutional network and secured by access code. Each Steering Committee Member is in charge for checking the quality and validity of her/his institution’s dataset. Auditing of the dataset will be performed every six months at institutional level by checking the data of 10 % of patients. Data without any patient identification code will be submitted to the principal investigator for further data checking and merging. The merged and checked dataset will be available to all E-CABG investigators for subanalyses.
Continuous variables will be reported as mean and standard deviation or median and interquartile range as needed. Dichotomous and nominal variables will be reported as counts and percentages. Missing data will not be replaced. Univariate analysis will be performed using the Mann–Whitney U test, Student’s t-test, Kruskall-Wallis test, Wilcoxon test, Fisher exact test, Chi-square test and Kaplan-Meier test. Multivariable analyses will be performed using logistic, classification tree, linear and ordinal regression methods as well as the Cox-proportional hazards method. Significant differences between study groups will be adjusted by using propensity score as covariate or one-to-one propensity score matching. Matching will be performed using a caliper width of 0.2 of the standard deviation of logit of the propensity score. Multiple propensity score adjusted analysis will be performed in case of multiple study groups. A Bayesian hierarchical approach will be used in case of significant between-centers variability.
Immediate and late outcome end-points
The primary outcome end-points will be defined according to the issue investigated in each study. The main immediate outcome end-points of studies from the E-CABG registry are: 1) In-hospital mortality and 30-day mortality, 2) stroke, 3) prolonged use of inotropes, 4) postoperative need of intra-aortic balloon pump (IABP) or extracorporeal mechanical oxygenation (ECMO), 5) immediate repeat revascularization, 6) wound infection and mediastinitis, 7) blood losses and use of blood products, 8) nadir hematocrit, 9) use of prothrombotics, 10) resternotomy for bleeding, 11) atrial fibrillation, 12) acute kidney injury and need of renal replacement therapy, 13) type V myocardial infarction, 14) pericardial effusion requiring treatment, 15) postoperative use of antibiotics, 16) delirium requiring drug treatment, 17) length of stay in the intensive care unit, and 18) length of in-hospital stay. The late outcome end-points of studies from the E-CABG registry are: 1) all-cause mortality, 2) cardiovascular mortality, 3) stroke, 4) myocardial infarction, 5) repeat revascularization and 6) a combined outcome end-point including any of these late adverse events. These end-points and their definition criteria are described in details in the following paragraphs of this article.
The research findings originating from data of the E-CABG registry will be disseminated in the scientific community by presenting the results of these studies in international congresses and publishing them in peer-review international journals in the fields of cardiac surgery and cardiology.
The data collection, analysis and writing process will be monitored by the Steering Committee of the E-CABG study. This Steering Committee is formed by a Principal Investigator and a Representative from each of the participating center. Participating centers and investigators are listed in Table 1. The Members of the Steering Committee will take the responsibility for the progress of data collection and its quality through local audit. The Steering Committee will evaluate any study proposal and accept/reject it by voting after having reviewed the study plan and discussed on its feasibility.
Authorship and the right to use of the registry data
Investigators will be eligible for authorship only if they contributed substantially to study planning, data collection, data analysis and interpretation, writing and critical revision of the manuscripts. In view of the major efforts that each center will face during data collection, one to three authors per each center will be included as main authors of each study performed using the E-CABG registry data. Members of the Steering Committee will decide about any co-authorship from her/his center. The researcher who plans the sub-study, performs the analysis and writes the article will have full right to be the first author of the study. The principal investigator will finalize the database and will guarantee that each Steering Committee Member will have a copy of the overall database as well as of any database created for sub-analyses.
Research ethics approval
The study has been approved by the local Institutional Review Board or Hospital Chief according to national guidelines for approval of registry studies. Patients’ informed consent is collected in institutions where it is mandatory.
Collection of baseline, operative and immediate postoperative outcome data has started on January 2015 and will end not before December 2015 with a minimum follow-up of 30-days. Follow-up data will be collected during January of each year for ten years. The first analyses of this dataset are expected on July 2015.
Baseline characteristics and operative data: definition criteria
Units of measurements
Units of measurements are likely to differ between centers. In order to avoid any problem during data merging and analysis, laboratory data will be collected according to the suggested units of measurement.
Baseline levels of hemoglobin, hematocrit, creatinine, platelets, blood glucose, HbA1c, C-reactive protein, TT-INR and platelets will be collected. Nadir hemoglobin and hematocrit levels as well as highest level of serum creatinine will be recorded as well.
Preoperative heart rate and blood pressure
These parameters are obtained in the operating room before anesthesia induction.
Preoperative drug treatment
Data on all antithrombotic drugs administered before surgery will be collected. The date of pause of drug treatment refers to the last day the patient received the drug.
Data on any oral or intravenous antibiotics administered preoperatively without prophylaxis purpose, i.e. for any preoperative infectious condition, will be collected.
Transient ischemic attack refers to any preoperative focal or global neurological syndrome caused by ischemia or hemorrhage resolving within 24 h.
Any preoperative focal or global neurological syndrome caused by ischemia or hemorrhage not resolving within 24 h.
Severe impairment of mobility secondary to musculoskeletal or neurological dysfunction.
One or more of the following: claudication, carotid occlusion or >50 % stenosis, amputation for arterial disease, previous or planned intervention on the abdominal aorta, limb arteries or carotids.
Diabetes requiring diet, oral or insulin treatment.
Arterial blood pressure > 140/90 mmHg or anti-hypertensive treatment.
Renal failure will be classified according to the estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease Study Group modified formula . eGFR for calculation of the EuroSCORE II  will be estimated using the Cockcroft-Gault formula  according to the criteria of this risk scoring method. The severity of renal failure will be classified in different stages as listed in Table 2.
Peritoneal or hemo-dialysis before surgery.
Functioning renal transplantation
Previous renal transplantation with preserved renal function.
Chronic lung disease
Any long term use of bronchodilators or steroids for lung disease.
Paroxysmal or persistent/permanent atrial fibrillation before surgery.
NYHA functional classes
Canadian Cardiovascular Society (CCS) class 4
Inability to perform any activity without angina or angina at rest, i.e., severe limitation.
Left ventricular function
Left ventricular ejection fraction recently before CABG (in any case before anesthesia induction).
Mitral valve regurgitation
Severity of mitral valve regurgitation before CABG graded in classes from 0 to IV.
Systolic pulmonary pressure
Systolic pulmonary pressure measured invasively before anesthesia induction. In case a thermodilution catheter is not inserted, systolic pulmonary pressure will be estimated at echocardiography.
Coronary syndrome refers to any of these conditions leading to the present hospital admission for CABG: 1) stable angina, 2) unstable angina requiring or not nitrates infusion, 3) non-ST elevation myocardial infarction, 4) ST-elevation myocardial infarction.
Urgency of the procedure
This will be graded according to the criteria listed in Table 4.
Ventricular tachycardia, ventricular fibrillation or asystole requiring this hospital admission or during hospital stay before CABG.
Out-of-hospital cardiac arrest
Cardiac arrest occurred out of the hospital and requiring the present hospital admission for CABG.
Critical preoperative status
Ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, preoperative inotropes or IABP, preoperative acute renal failure (anuria or oliguria <10 ml/hr).
Preoperative inotropic support
Preoperative use of epinephrine, norepinephrine, milrinone, amrinone, dobutamine, dopamine, levophed and/or levosimedan.
Preoperative use of IABP
Preoperative insertion of IABP before the start of CABG. This refers to any IABP insertion during coronary angiography, percutaneous coronary artery intervention or in the operating room, but before skin incision.
CSHA Clinical Frailty Scale
Grace score 2.0
This risk score is calculated using the on-line calculator available at http://www.euroscore.org/calc.html and reported in percentage. The risk factors included in the EuroSCORE II and collected in the E-CABG registry are defined according to the EuroSCORE II criteria .
Previous percutaneous coronary artery intervention
This registry included a number of variables to define accurately any details on previous PCI procedures. Data on the type of stent, either drug eluting or bare metal stents, is collected. Titanium stents are herein considered as bare metal stents. Balloon angioplasty refer to a PCI without stenting. Attempt to PCI with failure to pass the wire/stent through the occlusion/stenosis should not be considered as an accomplished PCI procedure. On the contrary, any PCI attempt resulting in coronary artery complication (thrombosis, dissection, perforation, etc.) should be considered as a prior PCI procedure. Details on PCI-related complications are retrieved as well.
Indication for CABG after PCI
The indication for CABG after any PCI procedure is defined as 1) stent thrombosis, 2) in-stent restenosis and/or 3) progression of disease.
CABG after PCI
Planned CABG after PCI is defined as a staged procedure in patients whose culprit lesions are treated first by PCI and in whom coronary surgery is planned to achieve complete myocardial revascularization immediately or shortly after PCI. Unplanned CABG refers to any surgical revascularization after PCI which was intended to provide definitive invasive treatment for coronary artery disease.
Number of diseased vessels
This refers to the number of vessels (one to three) with a stenosis of at least 50 % in the main artery (the left anterior descending artery, the circumflex artery and the right coronary artery) or their major branches.
Left main stenosis
This is defined as any stenosis ≥50 % of the left main trunk.
Equivalent to left main stenosis
This is defined as stenoses ≥70 % in the proximal segment of both the left anterior descending artery and the circumflex artery.
Data on type and dose of antibiotics administered prophylactically immediately or during surgery are collected.
This refers to surgeons who have operated in the preceding year at least on 20 patients using the off-pump technique.
Methods of revascularization are reported in Table 7.
This refers to epiaortic ultrasound performed to investigate the status of the ascending aorta.
Diseased ascending aorta
This is defined as any sign of atherosclerosis in the ascending aorta at palpation or epiaortic ultrasound.
This is defined as an extensive circumferential calcification of the ascending aorta.
Other intraoperative data
Details of the type of grafts used, number of distal anastomoses, the type of cardioplegia and its temperature as well as the duration of aortic cross-clamping, cardiopulmonary bypass and operation are collected.
Drug treatment at discharge
Data on treatment with aspirin, clopidogrel, ticagrelor, warfarin/Coumadin, low-molecular weight heparin, statins and/or ACE-inhibitors are collected.
Postoperative adverse events: definition criteria
Prolonged use of inotropics (>12 h)
This refers to the use of use of epinephrine, norepinephrine, milrinone, amrinone, dobutamine, dopamine, levophed and/or levosimedan for > 12 h after surgery.
This refers to postoperative insertion of an intra-aortic balloon pump device.
This refers to intra- or postoperative insertion of an extracorporeal mechanical oxygenation device.
Resternotomy for bleeding
This refers to any reoperation for hemostasis/removal of hematoma in presence of excessive bleeding with or without hemodynamic problem.
Resternotomy for hemodynamic problems
This refers to any reoperation for hemodynamic problems. This can be associated also with excessive bleeding: in such a case, both categories (Resternotomy for bleeding and Resternotomy for hemodynamic problems) are marked.
Sternal and leg wound infections
Wound complications are graded according to the Centers for Disease Control and Prevention definitions of surgical site infections . Any sternal or leg wound infection occurring within three months after surgery will be considered as postoperative wound infections.
Postoperative atrial fibrillation
It refers to any event of atrial fibrillation/flutter occurred after CABG and detected at ECG, requiring or not pharmacological/electrical cardioversion. Postoperative atrial fibrillation is defined paroxysmal if it is not detected at patient’s discharge. Otherwise atrial fibrillation is defined as permanent.
This complication is defined as any focal or global neurological syndrome occurring during the in-hospital stay caused by ischemia and/or hemorrhage not resolving within 24 h. The diagnosis and nature of stroke is made on the basis of findings at computed tomography and/or magnetic resonance imaging of the brain and confirmed by a neurologist. When neurological signs and symptoms disappear before discharge, stroke is defined temporary, otherwise it is defined as permanent.
Type 5 myocardial infarction
Delirium requiring drug treatment
Any postoperative neuropsychological syndrome requiring oral or intravenous drug treatment.
Blood loss 12 h after surgery
It refers to the amount of postoperative blood losses from mediastinal drainages within 12 h of surgery. Intraoperative blood losses are not taken in to account.
Hemoglobin nadir during the operation day
It refers to the lowest level of hemoglobin detected on the day of operation.
Hematocrit nadir during the operation day
It refers to the lowest level of hematocrit detected on the day of operation.
Highest postoperative creatinine level
It refers to the highest level of serum creatinine detected after surgery during the in-hospital stay.
Acute kidney injury
This end-point is defined as an increase in serum creatinine 1.5 -1.9 times the baseline level or serum creatinine increase≥26.5 μmol/l within seven days after surgery. This definition is according to the KIDGO criteria , but it considers only the change of postoperative serum levels of creatinine as outcome end-point. Therefore, acute kidney injury will be classified as listed in Table 9.
The need of renal replacement therapy is defined as temporary or permanent (in case the patient dies or is discharged on renal replacement therapy).
Red blood cell (RBC) units transfused intraoperatively
It refers to the amount of RBC units transfused intraoperatively (before the time “at chest closure”, see below). This does not refer to RBC units transfused before surgery or after the end of surgery.
RBC units transfused perioperatively
It refers to the overall amount of RBC units intra- and/or postoperatively transfused since the operation has started and till the day the patient is discharged home or to any other institution, i.e. intraoperative and postoperative. This does not refer to red blood cell transfused before surgery.
Use of fresh frozen plasma, solvent/detergent treated, pooled human plasma (Octaplas), platelets, rFVIIa, cryo-precipitate, fibrinogen and prothrombin complex concentrate
This refers to the use of these blood products used at the time of chest closure as well as after the operation until the day of discharge from the hospital. The amount of blood products are reported in homogenous units.
Severity of postoperative bleeding
This will be graded according to the Universal Definition of Perioperative Bleeding (UDPB) in adult cardiac surgery . Severe bleeding is defined as UDPB classes 3–4. Because of the complexity of this grading system, the E-CABG study group has developed its own grading system for a simple definition of severity of perioperative bleeding. The E-CABG investigators recognized that the amount of postoperative blood losses 12 h after surgery as defined by the UDPB criteria may not take into account the amount of intraoperative and postoperative bleeding occurring later on after surgery. Therefore the E-CABG investigators proposed a simple classification of perioperative bleeding based on the amount of RBC, platelets, fresh frozen/Octaplas units transfused during the intraoperative and postoperative period until the discharge. The methods adopted to stratify this outcome end-point are described in details in the paragraph “Classification of the severity of postoperative complications occurring immediately after surgery”.
Early repeated revascularization
This refers to any CABG and/or PCI performed during the same hospital stay for any graft and/or stent-related complication as well as for progression of coronary artery disease.
This refers to any gastrointestinal complication requiring endoscopy and/or surgical treatment.
Length of stay in the intensive care unit
This refers to the number of days the patient was treated in the intensive care unit (ICU) after surgery. Readmission to ICU is also taken in to account in the estimation of ICU stay.
Length of in-hospital stay
This refers to the number of days the patient was treated from the day of operation till the day of discharge from the hospital to any rehabilitation unit or home.
It refers to any death occurred in during the same hospital stay in the Institution where CABG was performed.
This refers to death occurring after discharge due to any cause. Specific causes of death are collected to better define whether death is related to any cardiovascular cause.
This refers to any focal or global neurological syndrome occurring after discharge and caused by ischemia and/or hemorrhage not resolving within 24 h. The diagnosis and nature of stroke is made on the basis of findings at computed tomography and/or magnetic resonance imaging of the brain and confirmed by a neurologist.
Late myocardial infarction
This refers to any myocardial infarction occurring after discharge and requiring medical or revascularization treatment. Since the current definition of type V myocardial infarction requires adequate validation, only myocardial infarction occurring after discharge will be considered as late myocardial infarction.
Late repeated revascularization
This refers to any CABG and/or PCI performed after discharge for graft and/or stent-related complication as well as for progression of coronary artery disease.
Combined outcome end-point
This refers to any of the main outcome end-point (all-cause mortality, stroke, myocardial infarction and/or repeat revascularization) occurring any time after CABG. Since the current definition of type V myocardial infarction requires adequate validation, only myocardial infarction occurring after discharge will be considered in this end-point.
Classification of the severity of postoperative complications occurring immediately after surgery
Adult cardiac surgery is associated with significant immediate postoperative mortality. Indeed, early mortality is generally considered a hard outcome end-point, and often the only one, of any analysis evaluating the outcome of cardiac surgery. However, the incidence of non-fatal complications after major surgery is rather high and may have a negative impact on patient’s recovery and the burden of resources necessary to treat such complications. Furthermore, postoperative complications may have a significant impact also on late survival [18–20].
The need of a grading system of postoperative complications has been recognized in surgery as a measure and a means to improve the quality of health care delivery . Therefore valuable ranking systems have been developed for the assessment of quality of surgical treatment as well as a reproducible tool in clinical research [21, 22]. However, the existing ranking systems are more suitable for patients undergoing non-cardiac surgery as they take into account minor complications which are very frequent in patients undergoing adult cardiac experience and which can be considered of minor prognostic importance in this subset of patients. Therefore, any method for grading the severity and prognostic implications of postoperative complications should be specifically tailored for adult cardiac surgery.
There are objective difficulties in ranking the postoperative complications after cardiac surgery as they may be related to a number of preoperative risk factors and perioperative treatment methods and importantly, relevant complications have not been thoroughly investigated in large clinical series. Therefore, there is a lack of data for a proper weighting of the prognostic impact of postoperative complications. Indeed, previous ranking methods used in non-cardiac surgery were not derived from statistical analyses of clinical datasets, but rather were proposed by a few experienced clinicians based on the current knowledge of the clinical impact of any minor and major postoperative complication. A more reliable method to stratify the clinical impact of any complications would be to retrieve the evidence of the negative impact of postoperative complication through meta-analytical methods. However, data for meta-analysis could be limited to a few major complications and may be lacking for many others.
The E-CABG investigators have selected 25 complications or interventions for their treatment (Table 10), which are believed to have a prognostic impact and possibly associated with increased resources for their treatment. These investigators recognized that in many cases, an intervention performed for any complication would provide a better stratification measure than considering the complication itself. Because of this, a number of complications are herein defined as any intervention performed for their specific treatment. These investigators decided to not enlist here some postoperative adverse events because of intrinsic difficulties in defining their true nature (for example: pneumonia, type V myocardial infarction, sepsis), because they are secondary to other more significant adverse events (for example: prolonged tracheal intubation) or any time interval may not capture the real extent of the event (for example: postoperative blood losses). These investigators recognized also the difficulty in identifying a valid definition of postoperative low-cardiac output syndrome. In fact, thermodilution catheter is not routinely used in many centers and the use of a cutoff of postoperative cardiac index to define this event is thus not feasible. Furthermore, postoperative use of inotropes varies significantly between institutions as their use after cardiac surgery is not limited to the treatment of markedly decreased cardiac index. Therefore, in this registry the definition of postoperative severely depressed cardiac function is reserved only to those conditions requiring postoperative insertion of IABP or ECMO.
Twenty-four E-CABG investigators have stratified the prognostic and severity burden of these 25 complications or interventions for their treatment giving a score from 0 to 10 to each of these adverse events/interventions. A score of 10 was supposed to measure the worst postoperative complication, i.e. patient’s death. Table 10 summarizes the mean, median and interquartile range of these scores.
The medians of these score were used to stratify the prognostic importance of each complication or intervention for its treatment (Table 11). Transfusion of one unit of RBC was considered not a significant event as both its mean and median scores were below 1. These investigators proposed a four grades classification method of postoperative complications in order to classify them according to their increasing severity. The fourth grade includes only the worst postoperative complication, i.e. patient’s death. Multiorgan failure was not herein considered a postoperative adverse events as this grading system includes most of the components of this syndrome. Table 11 summarizes also additive scores which are the rounded medians of Table 10. The sum of these scores for each complication/intervention occurring after CABG will be used as an additive score for further stratification of the prognostic importance of these events in each patient.
The E-CABG registry has been tailored to collect all the variables for stratification of perioperative bleeding according to the UDPB classification . However, the latter classification is rather complicated and includes a rather large number of differed blood products for treatment and prevention of excessive bleeding. Its use can be limited by the inclusion in this stratification method of the amount of blood losses. In fact, time interval (12 h after surgery) is supposed to not capture the real amount of bleeding occurring after cardiac surgery. Therefore, extrapolating the medians of Table 10, the E-CABG investigators propose a grading of the severity of intra- and postoperative bleeding based on the type and amount of blood products transfused during surgery and the in-hospital stay as well as on the need of reoperation for bleeding (Table 12). The authors propose also an additive score to better grade the need to treat severe intra- and postoperative bleeding.
This multicenter, prospective registry has been planned to investigate a number of controversial issues regarding the prognostic impact of baseline risk factors as well as treatment methods for surgical myocardial revascularization. This registry will provide also data on the role of pre- and postoperative pharmacological treatments on the outcome of patients undergoing CABG. These informations are expected to provide further knowledge on the mechanisms leading to adverse events after CABG and prevent them.
Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med. 2014;174:223–30.
Deb S, Wijeysundera HC, Ko DT, Tsubota H, Hill S, et al. Coronary artery bypass graft surgery vs. percutaneous interventions in coronary revascularization: a systematic review. JAMA. 2013;310:2086–95.
Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomized controlled trials. Lancet Diabetes Endocrinol. 2013;1:317–28.
Zheng H, Xue S, Lian F, Huang RT, Hu ZL, Wang YY. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg. 2013;43:459–67.
Hickey GL, Grant SW, Cosgriff R, Dimarakis I, Pagano D, Kappetein AP, et al. Clinical registries: governance, management, analysis and applications. Eur J Cardiothorac Surg. 2013;44:605–14.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med. 1999;130:461–70.
Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734–44.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
The Criteria Committee of the New York Heart Association Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels. Boston: Little Brown, 1964.
Killip 3rd T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457–64.
Rockwood K, Song X, MacKnight C, Bergman H, Hogan D, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.
Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4, e004425.
Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219–27.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250–78.
Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62:1563–70.
Acute Kidney Injury Work Group: Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline for acute kidney injury. Kidney Inter. 2012;2:1–138.
Dyke C, Aronson S, Dietrich W, Hofmann A, Karkouti K, Levi M, et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg. 2014;147:1458–63.
Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2015 (in press).
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF: Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth 2015, (in press)
Toumpoulis IK, Anagnostopoulos CE, Derose Jr JJ, Swistel DG. The impact of deep sternal wound infection on long-term survival after coronary artery bypass grafting. Chest. 2005;127:464–71.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
Strasberg SM, Linehan DC, Hawkins WG. The Accordion severity grading system of surgical complications. Ann Surg. 2009;250:177–86.
This study is not financially supported.
The authors declare that they have no competing interests.
About this article
Cite this article
Biancari, F., Ruggieri, V.G., Perrotti, A. et al. European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG registry): Study Protocol for a Prospective Clinical Registry and Proposal of Classification of Postoperative Complications. J Cardiothorac Surg 10, 90 (2015). https://doi.org/10.1186/s13019-015-0292-z
- Coronary artery bypass grafting